Online event

Bioavailability Challenge 2014

Bioavailability Challenge 2014

It is a well-established principal that even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it reaches the blood stream and is bioavailable.
But, while this characteristic - bioavailability - has been the focus of lab scientists, clinical researchers and process developers’ efforts for many years, finding the solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms.
Similarly, biopharmaceutical firms hoping to develop oral delivery alternatives for injectable biologics will also need to work out how to ensure that their products are bioavailable, safe and effective.
Our virtual event will bring together expert regulators, academics and the drug industry scientists to define the challenges and share the latest research breakthroughs to help you make the decisions that will let you overcome your Bioavailability Challenge.

Bioavailability market dynamics

11:00
1395918000
Local: GMT

A brief history of bioavailability

11:00
1395918000
Local: GMT

How glass-forming polymers improve bioavailability / Enhanced oral bioavailability with Soluplus® – case study

15:45
1395935100
Local: GMT

Dow AFFINISOL™ polymers for Solubility Enhancement

16:30
1395937800
Local: GMT

Role of excipients in design of solid amorphous drug dispersions for delivery of poorly water-soluble drugs

17:15
1395940500
Local: GMT